# Alentis Therapeutics

Source: https://onco.cc/companies/alentis-therapeutics/  
OnCo record `alentis-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Alentis Therapeutics targets Claudin-1, a protein exposed on squamous cancers and scarred organs, with antibodies that either carry a cancer-killing drug or block disease signalling. Its first cancer medicine entered human trials in 2025.

## Summary

Alentis Therapeutics is a clinical-stage Basel biotech focused on Claudin-1 (CLDN1), a tight-junction protein that becomes exposed on tumour cells and in fibrotic tissue. Its oncology pipeline comprises ALE.P02, a CLDN1-directed antibody-drug conjugate with a tubulin inhibitor payload for advanced or metastatic CLDN1-positive squamous solid tumours (FDA IND clearance October 2024, Fast Track designation November 2024, phase 1/2 trial planned from Q1 2025), and ALE.P03, a CLDN1 ADC with a topoisomerase 1 inhibitor payload entering first-in-human studies in 2025. The monoclonal antibody lixudebart (ALE.F02) is in development for organ fibrosis, with topline results in ANCA-associated glomerulonephritis and advanced liver fibrosis reported in January 2025. In November 2024 Alentis raised an oversubscribed USD 181.4 million Series D led by OrbiMed with co-leads Novo Holdings and Jeito Capital. Mark Pruzanski was appointed CEO in October 2025.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Basel
- Type: biotech
- Website: https://alentis.ch/

## Notes

- Earlier rounds (Series A to C) not fetched and omitted.

## Sources

- Official website: https://alentis.ch/
- Series D press release: https://alentis.ch/alentis-therapeutics-raises-181-4-million-in-an-oversubscribed-series-d-financing-to-advance-the-clinical-development-of-anti-claudin-1-adcs-in-solid-tumors/
- News: https://alentis.ch/news/

## Connected records

- fronts: [Antibody-Drug Conjugates](https://onco.cc/fronts/adcs/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- trials: [A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors](https://onco.cc/trials/nct06747585/), [A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors](https://onco.cc/trials/nct07169734/)
- companies: [Bpifrance](https://onco.cc/companies/bpifrance/), [Frazier Life Sciences](https://onco.cc/companies/frazier-life-sciences/), [Jeito Capital](https://onco.cc/companies/jeito-capital/), [Novo Holdings](https://onco.cc/companies/novo-holdings/), [OrbiMed](https://onco.cc/companies/orbimed/), [RA Capital Management](https://onco.cc/companies/ra-capital/)

---
JSON: https://onco.cc/api/v1/entities/alentis-therapeutics.json